Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)

Recruiting now · Phase 3

Conditions studied: Acute Kidney Injury Post Liver Transplantation

In brief

Liver transplantation (LT) is a high-risk surgery for hemodynamic instability and haemorrhagic shock with a high-risk of acute kidney injury (AKI). Indeed, the incidence of post-transplant AKI exceeds 50% in some series with 15% of patients requiring renal replacement therapy. Acute kidney injury after LT is a predisposing factor for chronic renal failure which is independently associated with higher morbidity and mortality. Arginine vasopressin (AVP), an essential stress hormone released in response to hypotension, binds to AVPR1a to promote vasoconstriction. Furthermore, it may have nephroprotective effects with a preferential vasoconstriction of the post-glomerular arteriole resulting in increased glomerular filtration The hypothesis of the present work is that low-dose arginine-vasopressin supplementation reduce posttransplant AKI in liver transplantation.

Key facts

Study ID

NCT06344442

Run by

Assistance Publique - Hôpitaux de Paris

People needed

304

Starts

2025-04-16

Expected to finish

2027-05-16

Last updated by the study team

2026-02-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Any adult patient with a scheduled liver transplantation
• All participants will need to be given clear information about the study and give signed informed consent.
• Person affiliated to the Social Security

You may not qualify if…

• Super-emergency for liver transplantation or fulminant hepatitis
• Patient listed for or receiving simultaneous liver-kidney transplantation (SLKT)
• Patients with end-stage renal disease (chronic eGFR < 15 mL/min/1.73 m2 or requiring extra-renal purification before liver transplantation
• Patient with epilepsy
• Hypersensitivity to arginine-vasopressin and to its excipients
• Patient refusal
• Patients for whom it is impossible to give informed consent (language barrier)
• Adults under guardianship or trusteeship, persons deprived of their liberty
• Patient enrolled in another interventional clinical study
• Pregnancy or breastfeeding

Where it is running

• URC Lariboisière-Fernand Widal-saint Louis — Paris, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.